Shionogi & Maze Gets Into Exclusive Worldwide License Agreement for MZE001

Shionogi & Maze Gets Into Exclusive Worldwide License Agreement for MZE001

By, Admin 14 May 2024

Shionogi, Maze Therapeutics announce exclusive worldwide license agreement for MZE001, an oral GYS1 inhibitor to treat Pompe disease

Overview

Shionogi & Co., Ltd., a leading global research-driven pharmaceutical company, and Maze Therapeutics, Inc., a biopharmaceutical company, announced the companies have completed an exclusive worldwide license agreement for the rights to MZE001, an investigational oral glycogen synthase 1 (GYS1) inhibitor that aims to address Pompe disease by limiting disease-causing glycogen buildup.
Pompe disease
Pompe disease is a rare, inherited disorder caused by mutations in the gene coding for acid alpha-glucosidase (GAA), which can lead to the buildup of glycogen in skeletal muscle, respiratory muscle and cardiac muscle tissues resulting in progressive weakness and respiratory compromise.

Terms of the Agreement

  • Under the terms of the agreement, Shionogi has acquired exclusive worldwide rights for MZE001 as well as related programmes and intellectual property. 
  • Shionogi will pay an upfront fee of $150 million, and Maze will be eligible for milestone payments based on development, regulatory and commercial achievements plus tiered royalties based upon future net sales. 
  • The required 30-day waiting period outlined in United States Hart-Scott-Rodino (HSR) Act has expired, and the transaction is completed.

Words from CEO: Shionogi

  • “This agreement is a strong strategic fit for Shionogi. It will help meaningfully advance our commitment to develop innovative medicines that address unmet medical needs and complement Shionogi's rapidly expanding pipeline in the focus areas designated in our Medium-Term Business Plan STS2030 Revision,” said Isao Teshirogi, Ph.D., CEO of Shionogi. 
  • “The science behind MZE001 is differentiated and promising, and we look forward to developing the compound as both mono and add-on therapy to enzyme replacement therapies.”

MZE001

  • MZE001 is a small molecule and specific inhibitor of GYS1, an enzyme involved in glycogen synthesis. 
  • It reduces the glycogen concentration in muscles by inhibiting this enzyme, and the results from the phase 1 study of MZE001 suggest that it has the potential to be the first oral therapy for the treatment of Pompe disease. 
  • MZE001 has the potential to be used both as a monotherapy option and as an add-on therapy with enzyme replacement, the current standard of care, to enhance the treatment of patients with Pompe disease.

Words from CEO: Maze

  • “Shionogi is committed to advancing and commercializing MZE001 because they understand the potential this therapy has for patients and the unmet medical needs it could address,” said Jason Coloma, Ph.D., CEO of Maze. 
  • “Shionogi has a track record of developing and delivering innovative medicines to patients worldwide, and we’re confident they are the right partner to continue to advance MZE001 through clinical trials so that it may reach patients with this life-threatening condition as soon as possible.”

ODD to MZE001

  • In 2022, the US Food and Drug Administration (FDA) granted Orphan Drug Designation to MZE001. 
  • The FDA grants Orphan Drug designation to prevent, diagnose or treat a rare disease or condition. 
  • Under the FDA's Orphan Drug Act, orphan drug status provides incentives, including tax credits, grants and waiver of certain administrative fees for clinical trials, and seven years of market exclusivity following drug approval.

Pompe Disease: In Japan

  • Pompe disease is a rare congenital metabolic disorder in which there is a deficiency of the enzyme necessary for the breakdown of glycogen within cells, resulting in the accumulation of glycogen in cells throughout the body, especially in muscle cells. 
  • This leads to various symptoms such as muscle weakness and delayed growth. In Japan, it has been designated as a ""specified rare disease"" and a ""specific paediatric disease,"" making it eligible for medical expense assistance programs and other forms of support.

Maze Therapeutics

Maze Therapeutics is a biopharmaceutical company that is harnessing the power of human genetics to transform the lives of patients, with a focus on genetically informed therapies for common diseases such as chronic kidney disease.

Shionogi & Co.

Shionogi & Co., Ltd. is a leading global research-driven pharmaceutical company dedicated to bringing benefits to patients based on its corporate philosophy of ""supplying the best possible medicine to protect the health and well-being of the patients we serve."

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!